Forbes March 4, 2024
Joshua Cohen

Biotechnology stocks are experiencing somewhat of a revival this year. It has even lifted some cell and gene therapy company share prices, though certainly not all of them. The continued lack of robust revenue for approved cell and gene therapies is a reminder that being innovative doesn’t necessarily translate into profitability.

Innovation in terms of novel therapies that address unmet need is unquestionably a good thing. Take for example, Elevidys (delandistrogene moxeparvovec). Last June, the Food and Drug Administration approved this first gene therapy for Duchenne muscular dystrophy via the accelerated approval pathway. Although questions remain about the long-term efficacy of the treatment, for the 3,500 boys who are affected by this debilitating genetic disorder Elevidys is addressing a serious...

Today's Sponsors


Today's Sponsor


Topics: Biotechnology, Pharma / Biotech
Biopharma M&A more than doubled in the first quarter compared to the year prior: report
Bruker brokers $392M deal for frayed NanoString
Pharma Pulse 4/18/24: Is it Fair Certain Biotech Investors Get an Early Look? The Health and Healthcare of Millennials & more
23andMine: CEO Wojcicki aims to take genetics company private
AI That Predicts Targeted Cancer Drug Response with Single-Cell Precision

Share This Article